Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the rectum meeting 1 of the following clinical (e.g., before neoadjuvant therapy) or pathologic staging criteria:~  * T3, N+, M0~ * T3, N0, M0~ * T4, N0, M0~ * Any T, N1-2, M0~* T4, N0-2, M0 disease must meet 1 of the following criteria:~  * Clinically fixed tumor on rectal examination with tumor adherent to the pelvic sidewall or sacrum~ * Hydronephrosis on Computed Tomography (CT) scan or Intravenous Pyelogram (IVP)~ * Ureteric or bladder invasion as documented by cystoscopy and cytology or biopsy~ * Invasion into prostate~ * Vaginal or uterine involvement~* Must have undergone complete tumor resection \>= 28 days ago and able to begin treatment by day 56~* Must have undergone concurrent neoadjuvant chemoradiotherapy\*~  * NOTE: \*Neoadjuvant chemoradiotherapy received on protocol NSABP-R-04 allowed provided it met these criteria~* Must have undergone prior radiotherapy at 40-55.8 Gy\*\* AND received 1 of the following chemotherapy regimens:~  * Continuous infusion of fluorouracil with or without oxaliplatin; fluorouracil and leucovorin calcium~ * Capecitabine with or without oxaliplatin; capecitabine with or without oxaliplatin OR a continuous infusion of fluorouracil with or without oxaliplatin received on protocol NSABP-R-04~ * NOTE: \*\*Intensity-modulated radiotherapy allowed~* ECOG performance status 0-1~* Platelet count \>= 100,000/mm\^3~* Absolute granulocyte count \>= 1,500/mm\^3~* Bilirubin normal (unless chronic grade 1 bilirubin elevation due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin)~* Alkaline phosphatase (AP) \< 2.5 times upper limit of normal (ULN) and aspartate aminotransferase (AST) \< 1.5 times ULN~* Hepatitis B and C negative (for patients with AP \> normal) unless previously vaccinated~* Serum creatinine =\< 1.5 times ULN~* Urine protein:creatinine (UPC) ratio \< 1.0 OR urine protein \< 1 g on 24-hour urine collection~* International Normalized Ratio (INR) =\< 1.5~* INR \> 1.5 allowed provided patient is on full-dose anticoagulants AND meets all of the following criteria:~  * In-range INR (i.e., between 2 and 3) on a stable dose of warfarin or low molecular weight heparin~ * No active bleeding or pathological condition that is associated with a high risk of bleeding~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study treatment~* No other previous or concurrent malignancy except nonmelanoma skin cancer, breast cancer in situ, carcinoma in situ of the cervix, or previously treated nonpelvic cancer that has been disease-free for \> 5 years~* Patients with a history of breast cancer (without evidence of disease) who remain on hormonal therapy for \> 5 years are eligible~* Patients with a history of hypertension must have blood pressure \< 150/90 mm Hg AND be on a stable regimen of antihypertensive therapy~* No other prior chemotherapy or pelvic radiotherapy except as neoadjuvant treatment for current diagnosis of rectal cancer~* Concurrent participation on protocol NSABP-R-04 allowed~Exclusion Criteria:~* Pregnant or nursing~* Evidence of metastatic disease on the surgical/intraoperative examination~* Evidence of metastatic disease confirmed by CT scan, Magnetic resonance imaging (MRI), or ultrasound of the liver or chest CT scan or chest x-ray within the past 6 months~* Evidence of tumor outside of the pelvis, including liver metastases, peritoneal seeding, or metastatic inguinal lymphadenopathy~* Concurrent major surgery~* Active bleeding not related to the primary rectal tumor within the past 6 months~* Active inflammatory bowel disease or other serious medical illness which might limit the ability of the patient to receive protocol therapy~* Active gastroduodenal ulcer determined by endoscopy~* Serious or nonhealing wound, skin ulcer, or bone fracture~* Clinically significant peripheral sensory or motor neuropathy \>= grade 2~* Nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study treatment including, but not limited to, any of the following:~  * New York Heart Association class III or IV congestive heart failure~ * Concurrent symptomatic arrhythmia~* Transient ischemic attack or cerebrovascular accident~* Arterial thromboembolic event, unstable angina, or myocardial infarction within the past 12 months~* Significant peripheral vascular disease~* Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude study requirements~* Significant traumatic injury within the past 28 days~* Known allergy to platinum compounds~* Prior invasive procedure, including either of the following:~  * Major surgical procedure or open biopsy within the past 28 days~ * Core biopsy or other minor procedure, except placement of a vascular access device, within the past 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
- Arm II (Type: EXPERIMENTAL): Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).